PiCT: 1st Recognition for Human Whole Blood on QCM-D Platform

Instruments for point-of-care (POC) coagulation monitoring for whole blood could reduce fundamental limitations of routine coagulation tests. ‘Prothrombinase induced Clotting Time’ (PiCT) is considered a universal assay for anticoagulants monitoring in laboratory and clinics but it has not been evaluated yet. It could reduce the inherited drawbacks of highly variability of results among different individuals in the activated partial thromboplastin time (aPTT) which is the most applied and clinical standard assay. In this report, PiCT for whole blood on quartz crystal microbalance with dissipation (QCM-D) platform for anticoagulant monitoring has been recognized for the first time. The present study demonstrates the lowest historical sample volume of human whole blood (as well as each reagent) consumption of 1.66 µL employed ever for coagulation. This is substantial support for launching spot test via QCM-D in laboratory and clinics and ultra-refining of POC settings. Different doses of danaparoid anticoagulant in blood samples (n=20) have been studied on QCM-D platform in parallel to ‘gold standard’. Both techniques demonstrated lower variability for anticoagulant with %RSD values between 3 and 8.5 depending on different anticoagulant doses. Data could be considered as precise and accurate for an anticoagulant recognition directly in blood using a clotting assay on QCM-D platform. Present study is crucial in the perspectives of robustness due to direct whole blood method on QCM-D platform and its cost-effectiveness due to lowest sample (as well as reagents) volume consumption.